Biogenerics - Backed by Robust Infrastructure

By the year 2010, biogenerics will constitute a significant 10% share of the global $100 billion biopharmaceuticals business.

Wockhardt is well prepared to tap this biogenerics opportunity, which is powered by its vision to introduce one biopharmaceutical product every year, and by the expiration of patents on blockbuster biopharmaceuticals worldwide.

The Company’s expertise in biopharmaceuticals is backed by robust manufacturing, regulatory and marketing infrastructure, offering huge opportunities for outsourcing and potential alliances with biotechnology leaders in the US and European Union.

Towards this end, Wockhardt has built comprehensive concept-to-market capabilities for biogenerics for the international markets. A sound regulatory infrastructure has been set up for its biogenerics pipeline with registrations in developing markets. The company has also set up front-end offices in the identified markets -- either owned organisations, strategic joint ventures or distribution arrangements.

Garnering registrations from international markets

Wockhardt has received more than 10 approvals from regulatory agencies in international markets. More applications are in the pipeline for approval in Russia, South America, Central Asia, South-East Asia, and North Africa. These markets offer huge opportunities as several high-value biotech medicines are due to come off patent in the next few years, offering opportunities to launch cost-effective versions with the potential of reaching more needy patients across the world.

Wockhardt’s Global Strategy for Biopharmaceuticals